|Bid||2.6200 x 45100|
|Ask||2.7000 x 3100|
|Day's range||2.4500 - 2.7200|
|52-week range||2.4500 - 11.1000|
|Beta (5Y monthly)||1.67|
|PE ratio (TTM)||N/A|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||6.33|
BOULDER, Colo., January 10, 2022--Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021. The financial information presented in this news release may be adjusted as a result of completion of customary quarterly review and audit procedures.
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
BOULDER, Colo., December 09, 2021--Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit